14
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Tumor markers after radiofrequency ablation therapy for hepatocellular carcinoma.

      Hepato-gastroenterology
      Adult, Aged, Aged, 80 and over, Biological Markers, blood, Carcinoma, Hepatocellular, mortality, surgery, Catheter Ablation, Cohort Studies, Disease-Free Survival, Female, Humans, Liver Neoplasms, Male, Middle Aged, Predictive Value of Tests, Protein Precursors, Prothrombin, Reproducibility of Results, Treatment Outcome, alpha-Fetoproteins, metabolism

      Read this article at

      ScienceOpenPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The aim of this study was to evaluate the clinical value of measurement of the AFP-L3 fraction before and after radiofrequency ablation (RFA) therapy for HCC, compared with the measurement of total AFP and des-gamma-carboxy prothrombin (DCP). One hundred and twenty-four patients with HCCs were evaluated for their complete response with a 5-mm-thick safety margin around the tumor. Three tumor markers (AFP, DCP, AFP-L3) were measured after RFA therapy, and their clinical significance was studied. Multivariate analysis revealed that of the three tumor makers only AFP-L3 showed significant differences in the survival and disease-free rates. AFP-L3 is the most reliable tumor marker for estimating overall survival and disease-free survival in patients with HCC effectively treated by RFA in contrast to AFP and DCP.

          Related collections

          Author and article information

          Comments

          Comment on this article